GÃ¼nter U HÃ¶glinger

List of Publications by Year
in descending order

251 papers	20,000 citations	17440 63 h-index	12597 132 g-index
267 all docs	267 docs citations	267 times ranked	28403 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
3	Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nature Neuroscience, 2004, 7, 726-735.	14.8	842
4	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	21.4	502
5	Extracellular Vesicle-Mediated Transfer of Genetic Information between the Hematopoietic System and the Brain in Response to Inflammation. PLoS Biology, 2014, 12, e1001874.	5.6	312
6	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurology, The, 2017, 16, 552-563.	10.2	303
7	Activation of the subventricular zone in multiple sclerosis: Evidence for early glial progenitors. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4694-4699.	7.1	299
8	The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Movement Disorders, 2014, 29, 1758-1766.	3.9	286
9	Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. Journal of Neurochemistry, 2003, 84, 491-502.	3.9	284
10	A phase 2 trial of the GSKâ€3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders, 2014, 29, 470-478.	3.9	251
11	The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3585-3590.	7.1	245
12	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	10.2	245
13	Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. Journal of Neurochemistry, 2003, 86, 1297-1307.	3.9	239
14	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	3.9	222
15	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
16	Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. Journal of Neurochemistry, 2004, 88, 63-69.	3.9	187
17	Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6632-6637.	7.1	184
18	The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. Journal of Neurochemistry, 2005, 95, 930-939.	3.9	183

#	Article	IF	Citations
19	Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinsonâ€™s disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Journal of the American Society for Mass Spectrometry, 2010, 21, 161-171.	2.8	181
20	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	3.9	179
21	Annonacin, a Natural Mitochondrial Complex I Inhibitor, Causes Tau Pathology in Cultured Neurons. Journal of Neuroscience, 2007, 27, 7827-7837.	3.6	176
22	Dopamine and adult neurogenesis. Journal of Neurochemistry, 2007, 100, 587-595.	3.9	173
23	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. European Journal of Neurology, 2009, 16, 297-309.	3.3	170
24	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
25	Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	9.0	145
26	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood, 2021, 138, 350-353.	1.4	145
27	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	5.7	141
28	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
29	Dopaminergic Substantia Nigra Neurons Project Topographically Organized to the Subventricular Zone and Stimulate Precursor Cell Proliferation in Aged Primates. Journal of Neuroscience, 2006, 26, 2321-2325.	3.6	138
30	Shortâ€term effects of coenzyme Q₁₀ in progressive supranuclear palsy: A randomized, placeboâ€controlled trial. Movement Disorders, 2008, 23, 942-949.	3.9	135
31	Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and Î±-synuclein-deleted mice. Experimental Neurology, 2008, 210, 182-193.	4.1	135
32	The Differential Diagnosis and Treatment of Atypical Parkinsonism. Deutsches Ärzteblatt International, 2016, 113, 61-9.	0.9	135
33	Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Movement Disorders, 2013, 28, 504-509.	3.9	132
34	Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Movement Disorders, 2014, 29, 479-487.	3.9	130
35	New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain, 2006, 129, 1194-1200.	7.6	124
36	Differential effects of social and physical environmental enrichment on brain plasticity, cognition, and ultrasonic communication in rats. Journal of Comparative Neurology, 2016, 524, 1586-1607.	1.6	122

#	Article	IF	Citations
37	<scp>COVID</scp>â€19 Vaccineâ€Associated Cerebral Venous Thrombosis in Germany. Annals of Neurology, 2021, 90, 627-639.	5.3	122
38	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
39	Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Movement Disorders, 2016, 31, 1506-1517.	3.9	120
40	Exosomal secretion of Î±-synuclein as protective mechanism after upstream blockage of macroautophagy. Cell Death and Disease, 2018, 9, 757.	6.3	117
41	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. Annals of Clinical and Translational Neurology, 2014, 1, 822-832.	3.7	114
42	Mitochondrial damage by Î±-synuclein causes cell death in human dopaminergic neurons. Cell Death and Disease, 2019, 10, 865.	6.3	112
43	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	8.4	111
44	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Science Translational Medicine, 2021, 13, eabe5640.	12.4	108
45	Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupe. Movement Disorders, 2005, 20, 1629-1633.	3.9	103
46	Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?. Brain, 2007, 130, 816-827.	7.6	99
47	<scp>PERK</scp> activation mitigates tau pathology inÂvitro and inÂvivo. EMBO Molecular Medicine, 2017, 9, 371-384.	6.9	93
48	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
49	Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Experimental Neurology, 2012, 238, 183-191.	4.1	92
50	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	7.7	90
51	A new dopaminergic nigro-olfactory projection. Acta Neuropathologica, 2015, 130, 333-348.	7.7	89
52	Rational therapeutic approaches to progressive supranuclear palsy. Brain, 2010, 133, 1578-1590.	7.6	83
53	Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. JAMA Neurology, 2018, 75, 860.	9.0	79
54	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2019, 18, 724-735.	10.2	79

#	Article	IF	Citations
55	Deficiency of Aph1B/C-Î³-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9775-9780.	7.1	77
56	Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Experimental Neurology, 2009, 220, 133-142.	4.1	76
57	Possible Involvement of Complement Factor C1q in the Clearance of Extracellular Neuromelanin From the Substantia Nigra in Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2011, 70, 125-132.	1.7	74
58	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	10.2	74
59	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
60	Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. Parkinsonism and Related Disorders, 2016, 33, 115-121.	2.2	72
61	In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS. Movement Disorders, 2010, 25, 1232-1238.	3.9	70
62	Systemic administration of neuregulinâ€‰Î²₁ protects dopaminergic neurons in a mouse model of Parkinsonâ€™s disease. Journal of Neurochemistry, 2011, 117, 1066-1074.	3.9	68
63	Manual MRI morphometry in Parkinsonian syndromes. Movement Disorders, 2017, 32, 778-782.	3.9	67
64	CXCR4 involvement in neurodegenerative diseases. Translational Psychiatry, 2018, 8, 73.	4.8	66
65	The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 22, S34-S36.	2.2	65
66	Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient. Frontiers in Neurology, 2020, 11, 576153.	2.4	64
67	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	30.7	63
68	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
69	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Frontiers in Aging Neuroscience, 2017, 9, 440.	3.4	58
70	Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons. Cell Death and Disease, 2014, 5, e999-e999.	6.3	56
71	Progressive supranuclear palsy: progression and survival. Journal of Neurology, 2016, 263, 380-389.	3.6	55
72	Neurodegenerative Diseases: Neurotoxins as Sufficient Etiologic Agents?. NeuroMolecular Medicine, 2008, 10, 1-9.	3.4	54

#	Article	IF	Citations
73	New insights into the relationship of neurogenesis and affect: tickling induces hippocampal cell proliferation in rats emitting appetitive 50-kHz ultrasonic vocalizations. Neuroscience, 2009, 163, 1024-1030.	2.3	53
74	Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy. Neurodegenerative Diseases, 2011, 8, 438-446.	1.4	53
75	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Movement Disorders, 2017, 32, 842-852.	3.9	52
76	Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Scientific Reports, 2017, 7, 11469.	3.3	52
77	Long-term treatment with l-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Neuropharmacology, 2015, 95, 367-376.	4.1	51
78	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology, 2021, 97, .	1.1	50
79	Atypical parkinsonism. Current Opinion in Neurology, 2013, 26, 401-405.	3.6	49
80	Î²-adrenoreceptors and the risk of Parkinson's disease. Lancet Neurology, The, 2020, 19, 247-254.	10.2	49
81	Rat fetal ventral mesencephalon grown as solid tissue cultures: influence of culture time and BDNF treatment on dopamine neuron survival and function. Brain Research, 1998, 813, 313-322.	2.2	48
82	Trifluoperazine rescues human dopaminergic cells from wild-type Î±-synuclein-induced toxicity. Neurobiology of Aging, 2014, 35, 1700-1711.	3.1	48
83	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	3.9	48
84	Cortical [<scp>¹⁸F</scp>]<scp>PI</scp>â€2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
85	Magnetic resonance imaging in progressive supranuclear palsy. Journal of Neurology, 2011, 258, 549-558.	3.6	44
86	Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. Frontiers in Behavioral Neuroscience, 2012, 6, 88.	2.0	44
87	Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy. Current Gene Therapy, 2014, 14, 343-351.	2.0	44
88	In vivo Evidence for Cerebral Depletion in High-Energy Phosphates in Progressive Supranuclear Palsy. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 861-870.	4.3	43
89	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nature Reviews Neurology, 2021, 17, 601-620.	10.1	41
90	Quantitative [123I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. NeuroImage, 2007, 38, 5-12.	4.2	39

#	Article	IF	Citations
91	Rostro-Caudal Gradual Loss of Cellular Diversity Within the Periventricular Regions of the Ventricular System. Stem Cells, 2009, 27, 928-941.	3.2	39
92	Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Experimental Neurology, 2014, 253, 113-125.	4.1	39
93	Psychosis in Parkinsonâ€™s disease: identification, prevention and treatment. Journal of Neural Transmission, 2016, 123, 45-50.	2.8	39
94	New classification of tauopathies. Revue Neurologique, 2018, 174, 664-668.	1.5	39
95	Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. Cell Death and Disease, 2021, 12, 854.	6.3	39
96	Safety and Tolerability of Pharmacotherapies for Parkinsonâ€™s Disease in Geriatric Patients. Drugs and Aging, 2019, 36, 511-530.	2.7	38
97	A brain-specific isoform of mitochondrial apoptosis-inducing factor: AIF2. Cell Death and Differentiation, 2010, 17, 1155-1166.	11.2	37
98	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
99	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
100	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. Movement Disorders, 2020, 35, 1245-1248.	3.9	37
101	In Vivo Assessment of Neuroinflammation in <scp>4â€Repeat</scp> Tauopathies. Movement Disorders, 2021, 36, 883-894.	3.9	37
102	A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin. Translational Neurodegeneration, 2022, 11, 28.	8.0	37
103	Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 462-466.	2.0	36
104	Origin of the dopaminergic innervation of adult neurogenic areas. Journal of Comparative Neurology, 2014, 522, 2336-2348.	1.6	36
105	A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs, 2016, 30, 629-636.	5.9	36
106	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	7.6	36
107	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
108	Memory deficits correlate with tau and spine pathology in <scp>P</scp>301<scp>S MAPT</scp> transgenic mice. Neuropathology and Applied Neurobiology, 2014, 40, 833-843.	3.2	35

#	Article	IF	Citations
109	Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. Journal of Neuroimmunology, 2011, 236, 39-46.	2.3	34
110	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinsonâ€™s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's Disease, 2022, 12, 557-570.	2.8	34
111	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
112	Fibroblast Growth Factor 2â€Mediated Regulation of Neuronal Exosome Release Depends on VAMP3/Cellubrevin in Hippocampal Neurons. Advanced Science, 2020, 7, 1902372.	11.2	33
113	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
114	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
115	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	3.9	31
116	Differentiation of atypical Parkinson syndromes. Journal of Neural Transmission, 2017, 124, 997-1004.	2.8	30
117	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. Frontiers in Aging Neuroscience, 2019, 11, 249.	3.4	30
118	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	2.4	30
119	Binding characteristics of [¹⁸F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	4.3	30
120	Neurotoxicity of Dietary Supplements from Annonaceae Species. International Journal of Toxicology, 2015, 34, 543-550.	1.2	29
121	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Movement Disorders, 2016, 31, 742-747.	3.9	29
122	Use of Î²2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology, 2019, 93, e135-e142.	1.1	29
123	Biodistribution and brain permeability of the extracellular domain of neuregulin-1-Î²1. Neuropharmacology, 2011, 61, 1413-1418.	4.1	28
124	Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No. Movement Disorders Clinical Practice, 2018, 5, 141-144.	1.5	28
125	Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. Journal of Neuroinflammation, 2020, 17, 374.	7.2	28
126	Early Neurodegeneration in the Brain of a Child Without Functional PKR-like Endoplasmic Reticulum Kinase. Journal of Neuropathology and Experimental Neurology, 2015, 74, 850-857.	1.7	27

#	Article	IF	Citations
127	Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wildâ€type and <scp>MAPT</scp> transgenic mice. Journal of Neurochemistry, 2016, 139, 624-639.	3.9	26
128	Neurological symptoms and complications in predominantly hospitalized COVIDâ€19 patients: Results of the European multinational Lean European Open Survey on SARSâ€Infected Patients (LEOSS). European Journal of Neurology, 2021, 28, 3925-3937.	3.3	25
129	Neurogenesis in Substantia Nigra of Parkinsonian Brains?. , 2009, , 279-285.		23
130	Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. Journal of the Neurological Sciences, 2015, 356, 129-136.	0.6	23
131	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.1	23
132	Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease. Neuroscience Letters, 2012, 531, 209-214.	2.1	22
133	Systemically administered neuregulinâ€1Î²1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in <scp>MPTP</scp> mouse models of Parkinson's disease. Journal of Neurochemistry, 2015, 133, 590-597.	3.9	22
134	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	3.9	22
135	Genotypeâ€“Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Movement Disorders, 2021, 36, 1499-1510.	3.9	22
136	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	6.4	22
137	A call for a global COVID-19 Neuro Research Coalition. Lancet Neurology, The, 2020, 19, 482-484.	10.2	22
138	Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinsonâ€™s Disease?. Brain Sciences, 2021, 11, 1654.	2.3	22
139	GBA-associated PD: chances and obstacles for targeted treatment strategies. Journal of Neural Transmission, 2022, 129, 1219-1233.	2.8	22
140	Mitochondrial Complex 1 Inhibition Increases 4-Repeat Isoform Tau by SRSF2 Upregulation. PLoS ONE, 2014, 9, e113070.	2.5	21
141	Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Neuropharmacology, 2014, 79, 212-221.	4.1	21
142	K-variant BCHE and pesticide exposure: Gene-environment interactions in a caseâ€“control study of Parkinsonâ€™s disease in Egypt. Scientific Reports, 2018, 8, 16525.	3.3	21
143	microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). Neurogenetics, 2016, 17, 165-171.	1.4	20
144	Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nature Communications, 2018, 9, 2929.	12.8	20

#	Article	IF	Citations
145	Zonisamide: Aspects in neuroprotection. Experimental Neurology, 2010, 224, 336-339.	4.1	19
146	Mitochondrial Dysfunction as a Therapeutic Target in Progressive Supranuclear Palsy. Journal of Molecular Neuroscience, 2011, 45, 684-689.	2.3	19
147	Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2012, 18, 606-608.	2.2	19
148	Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Current Opinion in Neurology, 2018, 31, 448-454.	3.6	19
149	Progressive supranuclear palsy. International Review of Neurobiology, 2019, 149, 49-86.	2.0	19
150	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. Journal of Neuroinflammation, 2020, 17, 208.	7.2	19
151	Alpha-synuclein fragments trigger distinct aggregation pathways. Cell Death and Disease, 2020, 11, 84.	6.3	19
152	One Year Trajectory of Caregiver Burden in Parkinsonâ€™s Disease and Analysis of Gender-Specific Aspects. Brain Sciences, 2021, 11, 295.	2.3	19
153	Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1020.	6.0	19
154	Experimental evidence for a toxic etiology of tropical parkinsonism. Movement Disorders, 2005, 20, 118-119.	3.9	18
155	Glia Protects Neurons against Extracellular Human Neuromelanin. Neurodegenerative Diseases, 2007, 4, 218-226.	1.4	18
156	Symptomatic therapy of multiple system atrophy. Autonomic Neuroscience: Basic and Clinical, 2018, 211, 26-30.	2.8	18
157	Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinsonâ€™s Disease. Brain Sciences, 2020, 10, 401.	2.3	18
158	Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinsonâ€™s disease. Acta Neuropathologica, 2020, 139, 319-345.	7.7	17
159	Neuropsychiatric Symptoms in Parkinsonâ€™s Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden. Brain Sciences, 2022, 12, 89.	2.3	17
160	Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinsonâ€™s Disease. Brain Sciences, 2020, 10, 111.	2.3	16
161	Piericidin A Aggravates Tau Pathology in P301S Transgenic Mice. PLoS ONE, 2014, 9, e113557.	2.5	15
162	Drug Safety Analysis in a Real-Life Cohort of Parkinsonâ€™s Disease Patients with Polypharmacy. CNS Drugs, 2017, 31, 1093-1102.	5.9	15

#	Article	IF	Citations
163	Towards a consensus on developmental regression. Neuroscience and Biobehavioral Reviews, 2019, 107, 3-5.	6.1	14
164	Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons. Neuropharmacology, 2019, 149, 13-26.	4.1	14
165	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Frontiers in Neurology, 2021, 12, 571800.	2.4	14
166	Treatment of upper limb spasticity with inhibitory repetitive transcranial magnetic stimulation: A randomized placebo-controlled trial. NeuroRehabilitation, 2021, 49, 425-434.	1.3	14
167	Nigrostriatal upregulation of 5â€HT_{2A} receptors correlates with motor dysfunction in progressive supranuclear palsy. Movement Disorders, 2009, 24, 1170-1175.	3.9	13
168	The influence of the CRS-R score on functional outcome in patients with severe brain injury receiving early rehabilitation. BMC Neurology, 2021, 21, 44.	1.8	13
169	Outcomes of <scp>SARSâ€CoVâ€2</scp> Infections in Patients with Neurodegenerative Diseases in the <scp>LEOSS</scp> Cohort. Movement Disorders, 2021, 36, 791-793.	3.9	13
170	Dual-Phase Î²-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 661284.	3.4	13
171	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13
172	Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry. NeuroImage, 2013, 79, 191-200.	4.2	12
173	One decade ago, one decade ahead in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1284-1293.	3.9	12
174	Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse. Scientific Reports, 2019, 9, 13359.	3.3	12
175	FGF2 Affects Parkinsonâ€™s Disease-Associated Molecular Networks Through Exosomal Rab8b/Rab31. Frontiers in Genetics, 2020, 11, 572058.	2.3	12
176	Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. Journal of Neurology, 2022, 269, 2403-2413.	3.6	12
177	Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. Journal of Neurology, 2011, 258, 1827-1834.	3.6	11
178	Tau Diagnostics and Clinical Studies. Journal of Molecular Neuroscience, 2017, 63, 123-130.	2.3	11
179	Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. Stem Cells Translational Medicine, 2017, 6, 576-588.	3.3	11
180	First symptom guides diagnosis and prognosis in neurodegenerative diseasesâ€”a retrospective study of autopsy proven cases. European Journal of Neurology, 2021, 28, 1801-1811.	3.3	11

#	Article	IF	Citations
181	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	2.4	11
182	Relationship Satisfaction in People with Parkinsonâ€™s Disease and Their Caregivers: A Cross-Sectional Observational Study. Brain Sciences, 2021, 11, 822.	2.3	11
183	Non-invasive and high-throughput interrogation of exon-specific isoform expression. Nature Cell Biology, 2021, 23, 652-663.	10.3	11
184	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. Frontiers in Neurology, 2021, 12, 684523.	2.4	11
185	c.207C>G mutation in sepiapterin reductase causes autosomal dominant dopa-responsive dystonia. Neurology: Genetics, 2017, 3, e197.	1.9	10
186	Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. Neurology, 2018, 90, 482-485.	1.1	10
187	Classification of atypical parkinsonism per pathology versus phenotype. International Review of Neurobiology, 2019, 149, 37-47.	2.0	10
188	Quantitative evaluation of the human subventricular zone. Brain, 2012, 135, e221-e221.	7.6	9
189	Current Treatment of Multiple System Atrophy. Current Treatment Options in Neurology, 2016, 18, 51.	1.8	9
190	Comprehensive miRNome-Wide Profiling in a Neuronal Cell Model of Synucleinopathy Implies Involvement of Cell Cycle Genes. Frontiers in Cell and Developmental Biology, 2021, 9, 561086.	3.7	9
191	Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 637176.	2.4	9
192	PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199368.	3.5	9
193	Analysis of Transition of Patients with Parkinsonâ€™s Disease into Institutional Care: A Retrospective Pilot Study. Brain Sciences, 2021, 11, 1470.	2.3	9
194	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurological Research and Practice, 2022, 4, 1.	2.0	9
195	Transcriptome and Proteome Analysis in LUHMES Cells Overexpressing Alpha-Synuclein. Frontiers in Neurology, 2022, 13, 787059.	2.4	9
196	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
197	Unbiased Screens for Modifiers of Alpha-Synuclein Toxicity. Current Neurology and Neuroscience Reports, 2019, 19, 8.	4.2	8
198	Genetic mimics of the non-genetic atypical parkinsonian disorders â€“ the â€˜atypicalâ€™ atypical. International Review of Neurobiology, 2019, 149, 327-351.	2.0	8

#	Article	IF	Citations
199	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 78, 200-203.	2.2	8
200	How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. Parkinsonism and Related Disorders, 2020, 81, 213-218.	2.2	8
201	Brain Morphological Alterations Are Detected in Earlyâ€Stage Parkinson's Disease with MRI Morphometry. Journal of Neuroimaging, 2020, 30, 786-792.	2.0	8
202	Differential expression of gut miRNAs in idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2021, 88, 46-50.	2.2	8
203	One-year outcome of brain injured patients undergoing early neurological rehabilitation: a prospective observational study. BMC Neurology, 2022, 22, 30.	1.8	8
204	Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation. Journal of Chemical Neuroanatomy, 2014, 61-62, 169-175.	2.1	7
205	l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons. Neuroscience, 2016, 331, 120-133.	2.3	7
206	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	2.2	7
207	Disease-modifying strategies in primary tauopathies. Neuropharmacology, 2020, 167, 107842.	4.1	7
208	Consensus-Based Recommendations for Advance Directives of People with Parkinsonâ€™s Disease in Regard to Typical Complications by German Movement Disorder Specialists. Journal of Clinical Medicine, 2020, 9, 449.	2.4	7
209	Auditory Stimulation Modulates Resting-State Functional Connectivity in Unresponsive Wakefulness Syndrome Patients. Frontiers in Neuroscience, 2021, 15, 554194.	2.8	7
210	Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinsonâ€™s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. Frontiers in Aging Neuroscience, 2022, 14, 851788.	3.4	7
211	Improved preparation of nasal lavage fluid (NLF) as a noninvasive sample for proteomic biomarker discovery. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 741-745.	2.3	6
212	Seizure prevalence in neurodegenerative diseasesâ€”a study of autopsy proven cases. European Journal of Neurology, 2022, 29, 12-18.	3.3	6
213	Does the Antiâ€Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? <scp>No</scp>. Movement Disorders Clinical Practice, 2021, 8, 1038-1040.	1.5	5
214	Cerebral Microstructural Alterations in Patients With Early Parkinsonâ€™s Disease Detected With Quantitative Magnetic Resonance Measurements. Frontiers in Aging Neuroscience, 2021, 13, 763331.	3.4	5
215	Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study. BMJ Neurology Open, 2022, 4, e000214.	1.6	5
216	Basic Fibroblast Growth Factor 2-Induced Proteome Changes Endorse Lewy Body Pathology in Hippocampal Neurons. IScience, 2020, 23, 101349.	4.1	4

#	Article	IF	Citations
217	iPS Cell-Based Model for MAPT Haplotype as a Risk Factor for Human Tauopathies Identifies No Major Differences in TAU Expression. Frontiers in Cell and Developmental Biology, 2021, 9, 726866.	3.7	4
218	Private variants in PRKN are associated with late-onset Parkinson's disease. Parkinsonism and Related Disorders, 2020, 75, 24-26.	2.2	4
219	Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Movement Disorders, 2011, 26, 901-905.	3.9	3
220	Reply to: â€œBrief Clinical Rating Scales Should Not Be Overlookedâ€• Movement Disorders, 2020, 35, 1886-1886.	3.9	3
221	Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017. Journal of Clinical Medicine, 2020, 9, 2454.	2.4	3
222	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. Clinical Neurology and Neurosurgery, 2020, 195, 105924.	1.4	3
223	DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy. Frontiers in Neurology, 2021, 12, 644064.	2.4	3
224	Validation of the Parkinsonâ€™s Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy. Parkinson's Disease, 2021, 2021, 1-7.	1.1	3
225	Neuropathology of progressive supranuclear palsy after treatment with tilavonemab â€“ Author's reply. Lancet Neurology, The, 2021, 20, 787-788.	10.2	3
226	Binding Stability of Antibodyâ€”Î±-Synuclein Complexes Predicts the Protective Efficacy of Anti-Î±-synuclein Antibodies. Molecular Neurobiology, 2022, 59, 3980-3995.	4.0	3
227	Hyperkalaemia in a tetraplegic adolescent due to de novo sodium channel mutation. Nephrology Dialysis Transplantation, 2007, 23, 1449-1451.	0.7	2
228	Diesterified Derivatives of 5-Iodo-2â€²-Deoxyuridine as Cerebral Tumor Tracers. PLoS ONE, 2014, 9, e102397.	2.5	2
229	Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. Journal of Neuroimmunology, 2014, 275, 165.	2.3	2
230	From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link. Movement Disorders, 2015, 30, 1871-1872.	3.9	2
231	Multiple System Atrophy. , 2017, , 183-192.		2
232	Reply to: â€˜Letter to the Editor on â€œCopathology Progressive Supranuclear Palsy: Does It Matter?â€â€™. Movement Disorders, 2020, 35, 2126-2126.	3.9	2
233	Evidence for pathogenicity of variant ATM Val1729Leu in a family with ataxia telangiectasia. Neurogenetics, 2021, 22, 143-147.	1.4	2
234	Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. Brain Sciences, 2022, 12, 204.	2.3	2

#	Article	IF	Citations
235	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2
236	Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go. Movement Disorders, 2017, 32, 1261-1262.	3.9	1
237	Tau links developmental to neurodegenerative diseases. Neuroscience and Biobehavioral Reviews, 2019, 104, 26-27.	6.1	1
238	18 Fâ€Plâ€2620 tauâ€PET in corticobasal syndrome (ActiGliA cohort). Alzheimer's and Dementia, 2020, 16, e041469.	0.8	1
239	Looking into the prediagnostic phase of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 74, 74-75.	2.2	1
240	<scp>LRP1</scp>: A Novel Mediator of Tau Uptake. Movement Disorders, 2020, 35, 1136-1136.	3.9	1
241	Patient Safety in a Box: Implementation and Evaluation of the Emergency Box in Geriatric and Parkinson Patients. Journal of Clinical Medicine, 2021, 10, 5618.	2.4	1
242	Inferring the sequence of brain volume changes in progressive supranuclear palsy using MRI. Brain Communications, 2022, 4, .	3.3	1
243	M. Parkinson â€“ ZukÃ¼nftige Therapieoptionen aus der Grundlagenforschung. E-Neuroforum, 2008, 14, 234-241.	0.1	0
244	Microglial activation in vivo is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039574.	0.8	0
245	Microglial activation and brain networks in Alzheimerâ€™s disease: The ActiGliA cohort study. Alzheimer's and Dementia, 2020, 16, e043265.	0.8	0
246	Author response: Use of Î²2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Neurology, 2020, 94, 899-899.	1.1	0
247	The â€œzig-zagâ€•sign in progressive supranuclear palsy â€“ The slowness of vertical saccades was the clue. Parkinsonism and Related Disorders, 2021, 83, 6-7.	2.2	0
248	Atypical pantothenate kinase-associated neurodegeneration with variable phenotypes in an Egyptian family. Heliyon, 2021, 7, e07469.	3.2	0
249	Reply to: â€œApplication of the <scp>mPSPRS</scp> to the Salerno Cohortâ€• Movement Disorders, 2021, 36, 2451-2452.	3.9	0
250	Associations between sex, body mass index, and the individual microglial response in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
251	Feasibility of short imaging protocols for [¹⁸ F]Plâ€2620 tauâ€PET in progressive supranuclear palsy. Alzheimer's and Dementia, 2021, 17, .	0.8	0